| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017 | 2928 | 2017 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research, 2016 | 471 | 2016 |
| A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal JX Sun, Y He, E Sanford, M Montesion, GM Frampton, S Vignot, JC Soria, ... PLoS computational biology 14 (2), e1005965, 2018 | 231 | 2018 |
| Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease R Yaeger, MA Shah, VA Miller, JR Kelsen, K Wang, ZJ Heins, JS Ross, ... Gastroenterology 151 (2), 278-287. e6, 2016 | 178 | 2016 |
| Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy AR Parikh, Y He, TS Hong, RB Corcoran, JW Clark, DP Ryan, L Zou, ... The Oncologist 24 (10), 1340-1347, 2019 | 79 | 2019 |
| Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling K Tarlock, S Zhong, Y He, R Ries, E Severson, M Bailey, S Morley, ... Oncotarget 9 (41), 26417, 2018 | 28 | 2018 |
| Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC). JA Elvin, Y He, J Sun, K Odunsi, JB Szender, KN Moore, LM Gay, ... Journal of Clinical Oncology 35 (15_suppl), 5512-5512, 2017 | 16 | 2017 |
| Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs) AB Schrock, D Fabrizio, Y He, J Chung, M Resnick, PJ Stephens, JS Ross, ... Annals of Oncology 28, v415, 2017 | 13 | 2017 |
| RVD2: an ultra-sensitive variant detection model for low-depth heterogeneous next-generation sequencing data Y He, F Zhang, P Flaherty Bioinformatics 31 (17), 2785-2793, 2015 | 6 | 2015 |
| Exceptional response to everolimus in a patient with metastatic castrate-resistant prostate cancer harboring a PTEN inactivating mutation JA Kmak, N Agarwal, Y He, AM Heilmann, VA Miller, JS Ross, SK Pal, ... Case Reports in Oncology 13 (1), 456-461, 2020 | 5 | 2020 |
| A validated diagnostic assay for identifying ovarian cancer patients with deleterious BRCA mutations and high genomic loss of heterozygosity (LOH) JX Sun, K Lin, Y Li, K Gowen, Y He, C Milbury, C Burns, J Luo, S Roels, ... Cancer Research 78 (13_Supplement), 4544-4544, 2018 | 2 | 2018 |
| Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors SM Ali, J Chung, N Dewal, LM Gay, Y He, ES Sokol, SZ Millis, JK Killian, ... Annals of Oncology 29, viii272, 2018 | 1 | 2018 |
| A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer JX Sun, Y Li, C Milbury, J Skoletsky, C Burns, W Yip, J Luo, N Dewal, ... Cancer Research 78 (13_Supplement), 4757-4757, 2018 | 1 | 2018 |
| Recurrent copy number variants are highly prevalent in acute myeloid leukemia K Tarlock, Y He, J Sun, RE Ries, EA Severson, M Bailey, S Morley, ... Blood 130, 3800, 2017 | 1 | 2017 |
| Characterization and Prevalence of a 3-Gene Biomarker Signature (PIK3CA, AKT1 and PTEN) for Selecting Breast Cancer (BC) Patients (Pts) for Treatment with the Oral AKT … M Wongchenko, Y He, J Elvin, S Trabucco, E Sokol, D Kim JOURNAL OF MOLECULAR DIAGNOSTICS 21 (6), 1188-1189, 2019 | | 2019 |
| A novel PI3K/Akt-pathway activation biomarker using comprehensive genomic profiling (CGP) for clinical trial assay Y He, M Wongchenko, J Skoletsky, C Burns, Y Li, P Maness, D Kim, ... Cancer Research 78 (13_Supplement), 2582-2582, 2018 | | 2018 |
| Comparative analysis of clinically validated NGS-based assays reveals high concordance across short variants NP Dewal, J Skoletsky, WK Yip, C Patriquin, Y He, JS Ross, VA Miller, ... Cancer Research 78 (13_Supplement), 417-417, 2018 | | 2018 |
| Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy. AR Parikh, Y He, TS Hong, RB Corcoran, JW Clark, DP Ryan, ... Journal of Clinical Oncology 36 (4_suppl), 43-43, 2018 | | 2018 |
| A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care J Sun, Y Li, C Milbury, J Skoletsky, C Burns, W Yip, J Luo, N Dewal, ... JOURNAL OF THORACIC ONCOLOGY 12 (11), S2117-S2118, 2017 | | 2017 |
| CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases N Dewal, Y He, RJ Lee, AB Schrock, J Chung, C Hoimes, ZR Chalmers, ... Cancer Research 77 (13_Supplement), 3394-3394, 2017 | | 2017 |
